Dr Doris Taylor, CEO RegenMedix Consulting LLC, is a dynamic scientist who has made field- changing innovations in regenerative medicine, stem cell profiling, and tissue engineering.
Based on her exceptional ability to reduce these complex topics to simple messages, she is also a highly sought after motivational and keynote speaker nationally and internationally at scientific, corporate, and medical conferences. She currently serves as a consultant in both the regenerative medicine and biotechnology space for government, academia, and industry.
Dr. Taylor helped create the field of cardiovascular regenerative medicine and is widely regarded as a major thought-leader in the field; her mechanistic insights and effective approaches to cardiac repair and replacement are well established and include a number of firsts. At Duke University Medical Center in 1998, she described the first functional repair of injured heart with cells – helping establish cardiovascular regenerative medicine. In 2000 recognizing that cells were heterogeneous and would persist in patients, she began to link individual cardiovascular cell product profiles to patient health and clinical trial outcome – building a capacity to reduce trial size and ask cutting edge questions about the roles of biologic sex, age, and race/ethnicity in cardiovascular regenerative medicine. In 2008, Taylor developed a whole-organ perfusion decellularization method that yielded an acellular solid organ scaffold with vasculature – transforming tissue and organ engineering possibilities. This was so revolutionary it was recognized as one of the “Top 10 Research Advances” by the American Heart Association and Taylor was nominated as one of “100 most influential people in the world” by Time magazine.
In 2009, Taylor co-founded Miromatrix Medical Inc. to commercialize decellularized/ recellularized products. Taylor holds 4 US and 28 international related patents and was recently elected as a senior member of the National Academy of Inventors. She continues to create academic-industry partnerships designed to build regenerative medicine solutions for patients.
Having served on the FDA Cell and Gene Therapy Advisory Panel, the Alliance for Regenerative Medicine Board/Executive Committee, and patient advocacy groups Taylor recognizes the critical importance of communication among scientists, sponsors, patients and regulators. She has been/is involved (inter)nationally on working committees for ESC, NHLBI, AHA, ACC, AABB, FACT, ISHLT, TERMIS, and the Standards Coordinating Body. She co-chairs the Advanced Regenerative Manufacturing Institute (ARMI) Tissue Manufacturing working group, serves on
the ARMI Leadership Advisory Council and is a member of the NIH-wide Regenerative Medicine Information Catalyst that is responsible for designing common data elements for basic, preclinical, and clinical regenerative medicine research funded under the 21st Century Cures Act.
Dr Taylor and her work has been featured by 60 Minutes, CNN, The New York Times, The Wall Street Journal, Associated Press, National Public Radio, and most worldwide media outlets. In 2019, she became a Senior member of the National Academy of Inventors.
Texas Heart Institute (2012- March 2020):
University of Minnesota Medical School (2003-2012):
Duke University School of Medicine (1991-2003):
Other Notable Professional Roles (selected)